TITLE

Updating the Management of Gout

AUTHOR(S)
Schumacher, H. Ralph
PUB. DATE
December 2009
SOURCE
International Journal of Advances in Rheumatology;2009, Vol. 7 Issue 4, p114
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Gout is increasing in prevalence and is associated with frequent co-morbidities; however, it is still often poorly managed. This update reviews the importance of an accurate diagnosis of the condition, as well as the current status of treatment of acute flares and the long-term management of hyperuricemia. Outcome targets are emphasized along with new information on pathogenesis and emerging therapies.
ACCESSION #
48381910

 

Related Articles

  • Gout. Rott, Keith T.; Agudelo, Carlos A. // JAMA: Journal of the American Medical Association;6/4/2003, Vol. 289 Issue 21, p2857 

    Discusses the diagnosis and treatment of gout. Presentation of the condition as acute inflammatory monarthritis; Misdiagnosis as cellulitis or septic arthritis; Discussion of hyperuricemia, which can be caused by overproduction or overexcretion of uric acid; Risk factors for hyperuricemia and...

  • Ätiologie und Management der Gicht. Pazár Maldonado, B.; So, A. // Zeitschrift für Rheumatologie;Feb2012, Vol. 71 Issue 2, p127 

    Gout is an inflammatory arthritis caused by monosodium urate (MSU) crystal deposits in and around the joint. The formation of urinary calculi can also occur in gout, but are less common than arthritis. Gout usually presents with recurrent episodes of joint inflammation, which over time lead to...

  • Stat Consult. Brier, Matthew // Clinical Advisor;Sep2009, Vol. 12 Issue 9, p55 

    The article offers information on gout. It is referred to a disorder which has a heterogeneous group of clinical presentations due to tissue deposition of monosodium urate crystals. Its causes and risk factors include urate underexcretion and overproduction as well as hyperuricemia. The...

  • GOUT NOT ROUTED YET. Hitchens, Kathy // Drug Topics;5/16/2005, Vol. 149 Issue 10, p26 

    This article discusses the pharmaceutical treatment of gout. The author contends that gout has evolved from a disease of the wealthy to a man's disease. Gout is associated with pain and disability to sufferers and as risk factor for coronary artery disease by healthcare professionals....

  • Oral versus Topical NSAIDs in Rheumatic Diseases: A Comparison. Heyneman, C.A.; Lawless-Liday, C.; Wall, G.C. // Drugs;Sep2000, Vol. 60 Issue 3, p555 

    Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed drugs worldwide and are responsible for approximately one-quarter of all adverse drug reaction reports. NSAIDs are widely prescribed for patients with rheumatic disease - a population at increased risk for...

  • Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Qaseem, Amir; Harris, Russell P.; Forciea, Mary Ann // Annals of Internal Medicine;1/3/2017, Vol. 166 Issue 1, p58 

    Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the management of gout. Methods: Using the ACP grading system, the committee based these recommendations on a systematic review of randomized, controlled...

  • Treatment of Septic Arthritis in Children. Jenson, Hal B. // Infectious Disease Alert;Jul2009, Vol. 28 Issue 10, p76 

    A RANDOMIZED, multicenter, open-label, parallel group, noninferiority trial of childhood septic arthritis was performed at seven referral hospitals in Finland from 1983-2005. The study included children 3 months to 15 years of age with acute septic arthritis, diagnosed by fever painful and...

  • Celebrex- The Instant Celebrity.  // Pharmaceutical Executive;Aug99, Vol. 19 Issue 8, p48 

    Offers a look at Celebrex, a nonsteroidal anti-inflammatory agent developed for osteoarthritis and rheumatoid arthritis. Cost effectiveness of the drug; Comments from Richard De Schutter, chief executive officer of Searle which manufactured the drug.

  • New Treatment for Osteoarthritis.  // Tufts University Health & Nutrition Letter;Jan2001, Vol. 18 Issue 11, p4 

    Provides information on several medications and treatment for osteoarthritis. Commendations on Vioxx and Celebrex, two anti-arthritis drugs which do not produce stomach ulcer; Complications brought by the intake of non-steroidal anti-inflammatory drugs; Challenges faced by arthritic patients...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics